Related Experiment Video
Updated: Jun 24, 2026
Single-cell RNA Sequencing and Analysis of Human Pancreatic Islets
Published on: July 18, 2019
Single-Cell RNA Sequencing Integrated with Bulk-RNA Sequencing Analysis Reveals Prognostic Signatures Based on
Jiyin Wang1,2,3,4,5, Xue Yin1,2,3,4,6, Ziyi Li1,2,3,4
1National Key Laboratory of Intelligent Tracking and Forecasting for Infectious Diseases, Beijing Ditan Hospital, Capital Medical University, Beijing, People's Republic of China.
Purpose:
Drug resistance severely compromises therapeutic efficacy in hepatocellular carcinoma (HCC); however, the selection of precise treatment strategies for patients remains a critical unmet clinical need. This study investigated PANoptosis-related mechanisms underlying HCC progression to identify actionable therapeutic targets and optimize patient-specific treatment outcomes.
Patients And Methods:
Multi-omics analysis (single-cell/bulk RNA sequencing) combined with machine learning was used to identify the PANoptosis-related prognostic features. The association of PANoptosis-related expression with the tumor immune microenvironment and drugs was explored using bioinformatic analysis and experimental studies.
Results:
High PANoptosis risk exhibited immunosuppressive microenvironments and therapeutic resistance. The PANoptosis-related gene YIF1B has emerged as a dual prognostic biomarker and tumor driver that promotes proliferation, and is linked to immune dysfunction and drug resistance.
Conclusion:
YIF1B may be a promising therapeutic target. This PANoptosis framework bridges molecular mechanisms to clinical management, offering strategies for personalized HCC therapy and overcoming treatment resistance.
Insights
This study reveals that high PANoptosis risk in hepatocellular carcinoma (HCC) is linked to immune suppression and drug resistance. The gene YIF1B is identified as a key driver and potential therapeutic target for personalized HCC treatment.
Area of Science:
- Oncology
- Immunology
- Genetics
Background:
- Drug resistance in hepatocellular carcinoma (HCC) significantly reduces treatment effectiveness.
- Developing precise treatment strategies for HCC patients is a critical unmet clinical need.
- Understanding the role of PANoptosis in HCC progression is essential for improving patient outcomes.
Purpose of the Study:
- To investigate PANoptosis-related mechanisms in HCC progression.
- To identify actionable therapeutic targets for HCC.
- To optimize patient-specific treatment strategies and overcome drug resistance.
Main Methods:
- Utilized multi-omics analysis, including single-cell and bulk RNA sequencing.
- Employed machine learning to identify PANoptosis-related prognostic features.
- Explored the association of PANoptosis-related gene expression with the tumor immune microenvironment and drug responses through bioinformatic and experimental studies.
Main Results:
- High PANoptosis risk was associated with immunosuppressive tumor microenvironments and therapeutic resistance in HCC.
- The PANoptosis-related gene YIF1B was identified as a prognostic biomarker and a driver of tumor progression.
- YIF1B expression correlated with immune dysfunction and drug resistance in HCC.
Conclusions:
- YIF1B represents a promising therapeutic target for hepatocellular carcinoma.
- The developed PANoptosis framework connects molecular mechanisms to clinical management strategies.
- This approach offers potential for personalized HCC therapy and overcoming treatment resistance.
More Related Videos
12:13Sequencing Small Non-coding RNA from Formalin-fixed Tissues and Serum-derived Exosomes from Castration-resistant Prostate Cancer Patients
Published on: November 19, 2019
07:32Author Spotlight: Investigating Immune Cell Dynamics in the Tumor Microenvironment — Challenges and Innovations in Cancer Prognosis
Published on: April 12, 2024
